Who Supplies Pioglitazone to India from UNITED KINGDOM

To import finished pharmaceutical formulations containing Pioglitazone into India, the importing company must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The Central Drugs Standard Control Organisation (CDSCO) requires that the product be registered, which involves submitting Form CT-20/40/41, depending on the product type. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), a No Objection Certificate (NOC) from the manufacturer, and stability data demonstrating compliance with Indian Pharmacopoeia standards. The timeline for import drug registration can vary but typically ranges from 6 to 12 months. For formulations under HS Code 30049099, specific requirements include detailed product information, manufacturing process details, and evidence of Good Manufacturing Practice (GMP) compliance.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product efficacy and safety in India's climate. Port inspections by customs drug inspectors are mandatory to verify the authenticity and quality of the imported products.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of finished pharmaceutical formulations, including Pioglitazone-containing products. The introduction of the Production Linked Incentive (PLI) scheme has encouraged domestic manufacturing, potentially affecting the volume of imports. Bilateral agreements with the United Kingdom have streamlined certain regulatory processes, but no significant changes have been noted in import policies during this period.

India imports finished Pioglitazone formulations primarily due to the demand for patented or branded products not manufactured domestically. Specific dosage forms, such as extended-release tablets, may not be produced locally, necessitating imports. Despite a robust domestic pharmaceutical industry, certain specialized formulations are sourced from abroad to meet market needs. The market size for Pioglitazone formulations in India is substantial, with a total export market of $37.3 million across 115 exporters to 70 countries.

The Basic Customs Duty for finished pharmaceutical formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable, along with a Social Welfare Surcharge (SWS) of 10%. These duties are standard for imports from the United Kingdom, as there is no Free Trade Agreement (FTA) between India and the UK. Anti-dumping duties are not currently imposed on Pioglitazone formulations. Exemption notifications are rare and typically apply to specific circumstances. The total landed duty percentage is approximately 32.1%.

India sources finished Pioglitazone formulations from the United Kingdom due to the availability of patented formulations and specialized dosage forms not produced domestically. The UK's pharmaceutical industry is known for high-quality standards and compliance with international regulations, providing a competitive advantage. Other suppliers include China, Germany, and the United States; however, the UK's share in this market segment remains significant.

India imports finished Pioglitazone formulations from the United Kingdom due to the availability of patented formulations and specialized dosage forms not produced domestically. The UK's pharmaceutical industry is known for high-quality standards and compliance with international regulations, providing a competitive advantage. Specific formulations, such as extended-release tablets, are sourced from the UK to meet market demand.

When compared to other origins like China, the European Union, and the United States, the United Kingdom offers advantages in terms of product quality, regulatory compliance, and reliability. While China may offer lower prices, concerns about quality and regulatory standards make the UK a preferred source for finished Pioglitazone formulations. The EU and US also provide high-quality products but may have higher costs and longer lead times.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to global supply chain issues, but the UK's consistent supply has mitigated these risks. Diversifying suppliers and maintaining buffer stocks are recommended strategies to manage these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) or Documents Against Payment (DA/DP) to manage cash flow.
4. 4Minimum Order Quantities (MOQs): Align order sizes with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.

1. 1DGFT Import License: Obtain a valid license from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation.
3. 3Form CT-20/40/41: Submit the appropriate form based on product type.
4. 4Certificate of Pharmaceutical Product (CoPP): Provide a CoPP from the manufacturer.
5. 5No Objection Certificate (N